Allbirds Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Allbirds Inc trades at $3 (market cap $26.33M), while Regeneron Pharmaceuticals Inc trades at $655.5 (market cap $69.52B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2640.3× Allbirds Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| BIRD | REGN | |
|---|---|---|
Market Cap | $26.33M | $69.52B |
Sector | Consumer Cyclical | Health |
52-Week High | $16.99 | $812.27 |
52-Week Low | $2.39 | $542.52 |
Enterprise Value | $45.20M | $63.47B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
BIRD (Smartbird) trades at $3.00, down 4.15% today, amid a complete business pivot from footwear to AI infrastructure. The stock shows a bearish technical trend with all moving averages signaling sell, while oscillators suggest potential oversold conditions. Fundamentally, the company reports declining revenue ($152M in 2025) and persistent losses (-$77M net income), though it maintains a low P/S ratio of 0.17. Recent news highlights the strategic shift, including a rebrand to Smartbird and appointment of a new CEO from Amazon Web Services (Reuters, June 17, 2026).
The outlook is highly speculative, driven by the unproven AI strategy rather than current fundamentals. Investment opportunity lies in potential AI sector growth, but risks include execution challenges, cash burn (-$40M net cash flow in 2025), and intense competition. Analysts are cautious with 79% hold ratings, reflecting uncertainty about the pivot's success. Shareholders face volatility as the company transitions from a tangible product business to technology infrastructure.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →